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Abstract 
In this study, we aimed to evaluate the protein expression profile of a spectrum of renal cell 
carcinomas (RCC) to find potential biomarkers for disease onset and progression and 
therefore, prospective therapeutic targets. A 2D-gel based proteomic analysis was used to 
outline differences in protein levels among different subtypes of renal cell carcinomas, in-
cluding clear cell carcinomas, papillary lesions, chromophobe tumors and renal oncocytomas. 
Spot pattern was compared to the corresponding normal kidney from the same patients and 
distinctive,  differentially  expressed  proteins  were  characterized  by  mass  spectrometry. 
Twenty-one protein spots were found differentially expressed between   c l e a r   c e l l   R C C   a n d  
normal tissue and 38 spots were found expressed in chromophobe tumors. Eleven proteins 
were identified, with most differentially expressed -b y   f o l d   c h a n g e - between clear cell tumors 
and the corresponding normal tissue. Two of the identified proteins, Triosephosphate iso-
merase 1 (TPI-1) and Heat Shock protein 27 (Hsp27), were further validated in a separate set 
of tumors by immunohistochemistry and expression levels were correlated with clinicopa-
thologic features of the patients. Hsp27 was highly expressed in 82% of the tumors used for 
validation, and all cases showed strong immunoreactivity for TPI-1. In both Hsp27 and TPI-1, 
protein expression positively correlated with histologic features of the disease. Our results 
suggest that the subjacent cytogenetic abnormalities seen in different histological types of 
RCC are followed by specific changes in protein expression. From these changes, Hsp27 and 
TPI-1 emerged as potential candidates for the differentiation and prognosis in RCC. 
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Introduction 
Renal cell carcinoma (RCC) represents the most 
c o m m o n   t u m o r   o f   t h e   k i d n e y   i n   a d u l t s   a n d   a c c o u n t s  
for  approximately  3%  of  all  adult  malignancies  in 
western  countries.  In  the  United  States alone, there 
were  estimates  of  more  than  54,000 new cases and 
about 13,010 deaths in 2008 (1).  
Historically RCC has been considered as a single 
entity. However, significant advances in the classifi-
c a t i o n   o f   t h e   d i s e a s e   d u r i n g   t h e   l a s t   d e c a d e ,   r e s u l t i n g  
from the combined application of molecular biology 
techniques and thorough histological examination of 
tumors, are now proving conclusively that renal  epi-
t h e l i a l   n e o p l a s m s   a r e   n o t   a   s i n g l e   t u m o r   b u t   r a t h e r   a  
group of distinguishable entities (2). The  disease  is 
heterogeneous,  with  an  often  unpredictable natural 
course  and  with  different  long-term  outcomes  for 
each  histological  subtype,  making  diagnosis  and 
treatment challenging.  
Cytogenetic  studies  of  renal  neoplasms  have 
documented  abnormalities  in  most  types  of  tumors, 
with chromosomal and genetic aberrations tending to 
b e   a s s o c i a t e d   w i t h   s p ecific  histopathologic  patterns Journal of Cancer 2010, 1 
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(3).  F o r   i n s t a n c e ,   c l e a r   c e l l   t u m o r s   u s u a l l y   s h o w   a  
highly specific deletion of chromosome 3p, papillary 
tumors show consistent chromosomal trisomies and 
loss of chromosome Y, and chromophobe type tumors 
are characterized by loss  of  heterozygosity  at  chro-
mosomes 1, 2, 6 and 10 (4). Such histology-genotype 
correlations  are  important,  not  only  in  highlighting 
t h e   b a s i c   t u m o r   b i o l o g y   f o r   e a c h   h i s t o l o g i c a l   t y p e ,   b u t  
also  in  predicti n g   t h e   d i f f e r e n t   p r o g n o s e s   f o r   e a c h  
t y p e   o f   t u m o r   (5). The complexity of RCCs is further 
increased due to the conditions in which the disease 
may appear. This is significant because R C C   i s   t h e  
most genetically heterogeneous cancer identified thus 
far,  with  tumors  appearing  in  a  range  of  sporadic 
cases as well in a myriad of hereditary syndromes (6).  
Although  genetic  and  cytogenetic  markers  are 
widely used in the diagnosis and follow up of RCCs, 
t h e   m a j o r i t y   o f   t u m o r   m a r k e r s   i n   r o u t i n e  use for epi-
thelial cancers are bas e d   o n   t h e   m e a s u r e m e n t   o f   s p e-
cific proteins, either immunohistochemically or as a 
circulating form. For instance, clear cell tumors highly 
express CD10 antigen, which is weakly expressed by 
p a p i l l a r y   t y p e   t u m o r s   a n d   i s   n e g a t i v e   i n   c h r o m o-
phobe and collecting duct tumors (7). The same is true 
f o r   t h e   c a r b o n i c   a n h y d r a s e   9   g e n e   p r o d u c t   ( C A 9 ) ,  
which  allows  the  differentiation  between  clear  cell 
type and chromophobe tumors (8). Such markers are 
i n   s o m e   w a y   r e l a t e d   t o   t h e   d i f f e r e n t   h i s t o l o g i c   o r i g i n s  
of each tumor type. 
Even though RCC, either in sporadic or familial 
form, h a s   b e e n   d e m o n s t r a t e d   t o   b e   a s s o c i a t e d   w i t h   t h e  
accumulation of different genetic alterations, the mo-
lecular mechanisms leading to the initiation and the 
progression of this disease are still not well unders-
tood (9). Whether these genetic abnormalities are fol-
l o w e d   b y   s p e c i f i c   c h a n g e s   i n   t h e   p r o t e i n   e x p r e s s i o n  
p r o f i l e s   h a s   n o t   b e e n   fully evaluated yet. We postulate 
that genetic abnormalities related to specific histologic 
p h e n o t y p e s   c a n   a l s o   b e   r e l a t e d   t o   s p e c i f i c   c h a n g e s   a t  
the  translational  level  (i.e.  protein  levels)  that  are 
characteristic  of  particular  histotypes.  The  present 
study therefore aimed to further categorize the diffe-
rential  protein  expression  profiles  i n   a   s p e c t r u m   of 
RCCs g r o u p e d   o n   t h e   b a s i s   o f   t h e i r   h i s t o l o g i c al fea-
tures. The goal is to identify potential molecular can-
didates that m a y   a i d   i n   t h e   c l a s s i f i c a t i o n   a n d   d iagno-
sis  of  the  disease  a n d   t h a t   m a y   r e p r e s e n t   p o s s i b l e  
targets in the clinical management of patients with 
kidney cancer. 
Materials and Methods 
Tissue collection and sample preparation 
Sixty-six samples  from RCCs and the surround-
ing noncancerous kidney tissues were obtained from 
surgical specimens after radical nephrectomy at  the 
NCI clinical center. The study protocol was approved 
by the Human Subject Research Committee,   a n d   t he 
specimens were procured and examined by a surgical 
pathologist  experienced  in  urologic  pathology.  The 
tumor  samples  used  for  proteomic  analyses  were 
snap-frozen  and  stored  at  -80°C until analysis. The 
remaining  parts  of  the  samples  were  taken  and 
processed for histological examination. The histopa-
thological classification of each tumor was performed 
a c c o r d i n g   t o   t h e   2 0 0 2   W H O   c r i t e r i a   (10). Tumor stage 
was determined according the 2002 AJCC TNM  stag-
ing system (11).  
Two frozen sections   ( 5 µ m   t h i c k )   w e r e   c u t   f r o m  
each  sample  and  briefly  stained  in  H-E  containing 
p r o t e a s e   i n h i b i t o r s .   E n r i c h e d   t u m o r   a n d   n o r m a l   c e l l  
populations were obtained by needle microdissection 
u n d e r   t h e   m i c r o s c o p e ,   a n d   h i g h l y   v a s c u l a r i z e d ,   n e-
crotic and inflammatory areas were avoided during 
cell procurement. Microdissected cells were collected 
i n   4 0   µ l   o f   l y s i s   b u f f e r   c o n s i s t i n g   o f   0 . 5 %   S D S   i n   H 2O 
containing  protease  inhibitors  and  immediately 
h e a t e d   a t   9 5 ° C   f o r   5   m i n .   O n e   m i c r o l i t e r   o f   l y s a t e   w a s  
u s e d   t o   m e a s u r e   p r o t ein concentration by a colorime-
t r i c   B C A   p r o t e i n   a s s a y .   P r o t e i n   y i e l d   w a s   h i g h l y   c o n-
s i s t e n t   a n d   r a n g e d   f r o m   2 . 2   t o   8 . 8   m g . m l -1.   T o t a l   p r o-
tein was then stored at -80°C until analysis. 
Two dimensional polyacrylamide gel electro-
phoresis (2D-PAGE)  
Before electrophoretic separation, samples were 
reduced  and  alkylated  with  tributylphosphine  and 
acrylamide respectively for 30 min in 200mM sodium 
bicarbonate buffer pH 8.0. Analytical and preparative 
2-D gels were performed by loading 50 µg and 1mg of 
protein  respectively,  onto  nonlinear  3–10 IPG-strips 
(130mm  Immobiline  Dry  Strips,  Amersham  Bios-
ciences, Piscataway, NJ) by in-gel rehydration in 250 
µ l   o f   u r e a   b u f f e r   ( 8   M   u r e a ,   2   M   t h i o u r e a ,   C H A P S   4 %  
w/v, 65mM DTT,  40mM Tris, 2% sulfobetaine, 2% 
Pharmalyte® 3–10) overnight. Isoelectric focusing was 
p e r f o r m e d   o n   a   M u l t i p h o r ® I P G   u n i t   ( A m e r s h a m   B i-
osciences, Piscataway, NJ)   f o r   a  total of 80 kVh, while 
the  second-dimension  w a s   c a r r i e d   o u t   o n   precast 
(J u l e ,   I n c .  M i l f o r d ,   C T ) 12.5% polyacrylamide slab gels 
in  SDS-PAGE  running  buffer.  Analytical  2-DE  gels 
were stained with an ammoniac silver solution, while 
preparative  gels  were  stained  with  0.1%   w / v   C B B  
R-250 in 0.5% v/v acetic acid: methanol (1:1; v/v) and 
d e s t a i n e d   o v e r n i g h t   w i t h   2 0 %   v / v   methanol:water. 
The gels were scanned w i t h   a   d i g i t a l   s c a n n e r   ( M i c r o-
Tek Scanmaker 8700, Microtek, Carson, CA)   i n   t r a n s-Journal of Cancer 2010, 1 
 
http://www.jcancer.org 
186 
f l e c t i v e   m o d e   a t   1 6   b i t   i m a g e   d e p t h   a n d   s t o r e d   i n   T I F  
format.  
Gel analysis  
Gels  were  analyzed  with  ImageMaster™  2D 
platinum software v6.0 (Amersham Biosciences Pis-
cataway,  NJ).  After image normalization and align-
ment,  the integrated volume  and  intensity  were de-
termined  for  each  identified  spot  in  triplicate  gels 
from  each  of  the  RCC  tissues  and  corresponding 
normal  kidney.  For  the  assessment  of  differentially 
expressed proteins, only statistically significant spots 
(p< 0 . 0 5   b y   S t u d e n t ’ s   t -test)  with  at  least  a  2-fold 
change that were altered in all tumor samples were 
selected for MS analysis and identification. Because 
the  a i m   o f   t h i s   s t u d y   w a s   biomarker identification, 
only differentially over expressed proteins spots were 
used  for  peptide  identification.  Furthermore,  only 
s p o t s   t h a t   w e r e   c h a r a c t e r i s t i c a l l y   p r e s e n t   i n   o n e   h i s-
tological subtype but not in the others were recovered 
for MS analysis.  
In-gel digestion, sample preparation for 
MALDI-MS and protein identification 
Differentially expressed protein spots were ex-
cised from gels, destained and dehydrated by  wash-
ing 2 times for 10–15 min with 50mM NH4HCO3 in 
30% CH3CN. The destained spots were then dried for 
30 min under vacuum, covered with digestion buffer 
(50mM NH4HCO3 buffer, pH 8.5) and digested over-
night  with  trypsin  (0.06  mg.ml-1)  by  incubation  at 
3 7 ° C .   P o l y p e p t i d e s   w e r e   t h e n   e x t r a c t e d   w i t h   2 0   µ l   o f  
1% TFA and the supernatant was removed. A second 
extraction was pe r f o r m e d   w i t h   2 5   µ l   o f   0 . 1 %   T F A   i n  
50% CH 3CN.   T h e   t w o   e x t r a c t s   a n d   t h e   d i g e s t i o n   b u f-
f e r   w e r e   f i n a l l y   p o o l e d   a n d   c o n c e n t r a t e d   b y   v a c u u m  
to  3–5  µl.  Tryptic  digests  were  analyzed  using  ma-
trix-assisted  laser  desorption/ionization  (MALDI) 
time of flight (MALDI-T O F )   m s   o r   m s / m s   m a s s   s p e c-
trometry  using  α-cyano  4-hydroxy  cinnamic  acid  as 
the carrier matrix. The MALDI spectra generated with 
a   m a s s   a c c u r a c y   o f   2 0   p p m   a n d   m a x i m u m   n u m b e r   o f  
missed  cleavages  set  to  one  were  averaged  over 
200–400  laser  shots,  and  peptide  masses  were  sub-
m i t t e d   t o   S w i s s P r o t   a n d   N C B I n r   d a t a b a s e s   f o r   p eptide 
mass fingerprinting and protein identification using 
MS-Fit  for  ms  data  search  [http://prospector.ucsf. 
edu/] or MASCOT MS/MS v1.8 Ion Search (Matrix 
Science, London, UK) for  ms/ms  data  analysis.  The 
M A L D I   m a s s   d a t a   w e r e   i n t e r n a l l y   c a l i b r a t e d   w i t h   t h e  
masses  of  two  trypsin  autolysis  products  of  known 
amino acid sequence. Contaminant ions from keratin 
and trypsin were not included in the results. A min-
imum of four statistically significant unique peptides 
were considered as positive protein identification. 
Immunohistochemistry  
Formalin-fixed, paraffin embedded (FFPE) sam-
p l e s   w e r e   u s e d   f o r   v a l i d a t i n g   t h e   i d e n t i f i e d   p r o t e i n s   i n  
t i s s u e s .   T h i s   w a s   c a r r i e d   o u t   i n   a n   i n d e p e n d e n t   s e t   o f  
samples. Twenty-f i v e   s a m p l e s   c o n t a i n i n g   t u m o r   a n d  
n o r m a l   t i s s u e   w e r e   r e t r i e v e d   f r o m   t h e   p a t h o l o g y   a r c-
h i v e s   o f   t h e   N C I   a n d   t e s t e d .   T h e   i n d i r e c t   h o r s e r a d i s h  
peroxidase (HRP)-l a b e l e d   a n t i b o d y   m e t h o d   w a s   e m-
p l o y e d   f o r   t h e   i m m u n o s t a i n i n g   a s   d e s c r i b e d   p r e-
viously (12).   I n   b r i e f ,   5   µ m -thick sections were placed 
on positive-charged slides and deparaffinized at 60°C 
30 min, followed by immersion in Xylene 3 changes of 
5   m i n   e a c h .   A f t e r   r e h y d r a t i o n   i n   a   s e r i e s   o f   g r a d e d  
alcohols, heat-induced antigen retrieval in a solution 
of  either  citrate b u f f e r   p H   6 . 0   o r   T r i s -EDTA  pH  8.0 
w a s   c a r r i e d   o u t   i n   a   m i c r o w a v e   o v e n   f o r   2 0   m i n   a t  
9 5 ° C .   S a m p l e s   w e r e   a l l o w e d   t o   c o o l   a t   r o o m   t e m p e r-
a t u r e   ( R T )   a n d   w e r e   t r e a t e d   w i t h   a   s o l u t i o n   o f   0 . 3 %  
hydrogen peroxide in methanol for 10 min to inacti-
vate endogenous peroxidase. Slides were washed in 
T B S T   3   c h a n g e s   o f   5   m i n   e a c h ,   a n d   t h e n   i n c u b a t e d  
with either purified mouse anti-heat shock protein 27 
(Hsp27) antibody (final concentration 1 µg.ml-1,  Cell 
signaling,  Danvers,  MA)  overnight  at  4°C  or  with 
rabbit  anti-Triosephosphate  Isomerase  1  (TPI-1,  1 
µg.ml-1,  Proteintech,  Chicago,  IL  )   f o r   1   h r .   a t   R T .  
These two concentrations were found to provide the 
best  signal-to-noise  ratio  after  dilution  testing.  In  a 
subset of FFPE tissues, antibodies for Apolipoprotein 
A-1,  Superoxide  dismutase,  Alpha-enolase  and  Pe-
roxiredoxin 2 were also evaluated. Isotype-matched 
antibodies raised in the same species were substituted 
for  the  primary  antibodies  and  served  as  negative 
controls.  Appropriate  positive  controls  were  run  in 
parallel. Sections  were  subsequently  incubated  with 
HRP-labeled secondary antibodies for 30 min at room 
temperature, and the reactions were developed with 
0.025% 3,3’-diaminobenzidine solution containing 10 
mM hydrogen peroxide, lightly counterstained with 
Mayer’s hematoxylin, and permanently mounted for 
o b s e r v a t i o n .   A t   l e a s t   t w o   d i f f e r e n t   s e c t i o n s   p e r   s a m p l e  
were  analyzed,  and  staining  was  annotated  as  fol-
l o w s :   0 ,   n e g a t i v e ;   1 + ,   w e a k   p o s i t i v e ,   w h e n   l e s s   t h a n  
1 0 %   o f   t h e   c e l l s   w e r e   p o s i t i v e ;   2 + ,   p o s i t i v e ,   1 1 –50% 
positive  cells;  3+  strongly  positive,  more  than  50% 
positive cells. Cellular localization of the immunos-
taining, nuclear or cytoplasmic, was also recorded. 
Statistical analysis 
T h e   s a m p l e   s i z e   o f   2 5   p a t i e n t s   i n   t h e   v a l i d a t i o n  
group allowed us to estimate at least a 35% difference Journal of Cancer 2010, 1 
 
http://www.jcancer.org 
187 
in  protein  expression  between  samples  with  80% 
power at an alpha probability value of 0.05. The rela-
t i o n s h i p   b e t w e e n   p r o t e i n   m a r k e r s   a n a l y z e d   b y   i m-
munohistochemistry  and  clinicopathological  factors 
was  analyzed  with  the  Fisher’s  exact  test  based  on 
10.000 resamples. Statistical analysis were conducted 
using SPSS v13.0 (SPSS, Chicago IL), and significance 
was defined as a p value <0.05. 
Results 
Patients’ characteristics 
We analyzed the proteomic profiles of the RCC 
tissue and the corresponding normal kidney tissues in 
66 samples from 22 patients with RCC. The mean age 
o f   t h e   p a t i e n t s   w a s   5 3   y e a r s   ( r a n g e   3 9   t o   8 8 ) .   F o u r t e e n  
c l e a r   c e l l   R C C ,   4   c h r o m o p h o b e ,   2   p a p i l l a r y   t y p e   I   t u-
mors  and  two  oncocytomas  were  included, 
representing the spectrum of th e   m o s t   c o m m o n l y   s e e n  
histologic types of renal neoplasms. Table 1 summa-
rizes the clinical and pathological features of the pa-
t i e n t s   w i t h   R C C   i n c l u d e d   f o r   b o t h   t h e   p r o t e o m i c  
analysis and for validation. The formalin-fixed paraf-
fin  embedded  samples  used  for  the  analysis  com-
p r i s e d   a   g r o u p   o f   2 5   t u m o r s .   T h e   m e a n   a g e   o f   t h i s  
second group of patients was 48 years (range: 38-64). 
M o s t   w e r e   c l e a r   c e l l   t u m o r s ,   a l t h o u g h   o t h e r   s u b t y p e s ,  
s u c h   a s   p a p i l l a r y   t u m o r s   a n d   o n c o c y t o m a s ,   w e r e   a l s o  
included. The difference in the distribution of cases 
between the two cohorts did not reach statistical sig-
nificance. 
Differential protein expression 
A n   a v e r a g e   o f   9 0 5   s p o t s   f r o m   R C C   s a m p l e s   a n d 
850 spots from a corresponding normal kidney sam-
p l e s   w e r e   t y p i c a l l y   v i s u a l i z e d   i n   a   g e l   ( p H range from 
3.0-10.0 and a molecular mass range from 10-250 kDa). 
The overall protein expression patterns in RCC and 
n o r m a l   k i d n e y   t i s s u e s   w e r e   s i m i l a r   e x c e p t   f o r   s o m e  
areas (Fig. 1 A-C).  
Twenty-one  proteins  spots  were  found  to  be 
differentially  expressed  between  the  clear  cell  RCC 
a n d   n o r m a l   t i s s u e .   F r o m   t h e s e ,   e i g h t   s p o t s   w e r e   s e-
lected  and  identified  by  MS.  These  included  Heat 
Shock protein 27 (Hsp27), Triosephosphate isomerase 
1  (TPI-1 ) ,   P e r o x i r e d o x i n   2   ( P R X -2 ) ,   a n d   A p o l i p o-
protein A-1 precursor (APO-A1) among others. Thir-
ty-eight differentially expressed spots were found in 
chromophobe tumors and 4 were selected for further 
analysis,  which  resulted  in  2  identifications, 
ZnCu-Superoxide Dismutase (SOD) and the UV exci-
sion repair protein RAD23B. Alpha-Enolase  (ENOA) 
was the only identified protein from the renal onco-
cytomas, while no significantly different spots could 
b e   f o u n d   b e t w e e n   p a p i l l a r y   t y p e   I   t u m o r s   a n d   t h e  
corresponding non-neoplastic tissue. Differential ex-
pression levels for some representative polypeptides 
i n   R C C s   a n d   t h e   c o r r e s p o n d i n g   n o r m a l   t i s s u e   a r e  
shown in Fig. 1 G-I.  
 
Table 1. Clinicopathologic characteristics of the patients and samples used for the proteomic analysis and protein valida-
tion. No statistically significant difference for the distribution of cases was found. 
Variable  Cases used for protein identification 
(Discovery group) 
Cases used for immunohistochemistry 
(Validation group) 
p-value* 
  N  (%)  N  (%)   
Sex          0.773 
  Male  11  50  14  56   
  Female  11  50  11  44   
Age (yrs)          0.087 
  mean (range)  53  (39-88)  48  (38-64)   
Histology          0.862 
  Clear cell  14  64  19  76   
  Papillary  2  9  2  8   
  Chromophobe  4  18  3  12   
  Oncocytoma  2  9  1  4   
Histological grade          0.760 
  1-2  9  45  9  36   
  3-4  11  55  16  64   
TNM stage          0.224 
  I-II  14  70  12  48   
  III-IV  6  30  13  52   
 Journal of Cancer 2010, 1 
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Figure 1. Representative 2-D PAGE images. F u l l   g e l s   a r e   s h o w n   f o r  normal kidney (A), a clear cell carcinoma (B) and a 
chromophobe tumor (C). Composite images (master gels) resulting from combining all samples are shown in panels D-F   a l s o  
for normal, clear cell and chromophobe tumors. Differentially expressed protein spots are shown in panels G-I   a s   i n d i c a t e d  
by arrowheads.  
 
Overall, 11 proteins were identified, with most 
differentially  expressed  proteins  found  between  the 
c l e a r   c e l l   t y p e   a n d   t h e   c o r r e s p o n d i n g   n o r m a l   k i d n e y .  
The predicted and experimental values of isoelectric 
point  (pI),  molecular  weight  (Mw)  and  relative  ex-
pression levels for all identified proteins are summa-
rized in Table 2. The average fold change for these 
differentially expressed proteins in RCC ranged from 
2 . 1   t o   1 3 . 5   f o l d .   T h e   s e q u e n c e   c o v e r a g e   o f   p r o t e i n s  
isolated from the peptide mass matching ranged from 
9  to  57%.  Functional  annotation  analysis  of  these 
proteins demonstrated that the majority (5/11, 45.5%) 
of  these  polypeptides  were  related  to  metabolic 
pathways. The remaining proteins not related to me-
tabolism were either acute phase reactants or stress 
response proteins.  
Immunohistochemical validation 
T o   v a l i d a t e   o u r   2 -D protein expression results, 
we  performed  immunohistochemical  analysis  to 
evaluate the tissue expression of two of the differen-
tially  expressed  pro t e i n s   f o u n d   b y   t h e   p r o t e o m i c  
analysis. The selected proteins, Hsp27 and TPI-1 were 
chosen as representative of their functional annotation 
family,  stress  response  proteins  and  metabol-
ism-related proteins respectively. Almost seventy per 
cent of the tumors highly expressed Hsp27 (2+ or 3+), 
with most of them showing cytoplasmic staining (Fig. 
2A-D, Table 3). Staining intensity was usually strong 
when compared to the intensity of endothelial cells 
(internal  positive  controls).  Glomeruli  were  consis-
tently nega t i v e   a n d   e x p r e s s i o n   i n   t h e   t u b u l e s   w a s   v a-
riable (Fig. 2E-F). In all cases, isotype-matched nega-
tive controls resulted in negative staining (Fig.  2H). 
Triosephosphate Isomerase 1 was found expressed in 
all cases tested. The staining was cytoplasmic in all 
c a s e s ,   e v e n   t h o u g h   n u c l e a r   s t a i n i n g   w a s   o b s e r v e d   i n  
8 2   %   o f   t h e   s a m p l e s   ( Fig.  3A-D) .   I n   a   s u b g r o u p   o f  
F F P E   s a m p l e s ,   o t h e r   p r o t e i n s   s u c h   a s   A l p h a -Enolase, 
Peroxiredoxin 2, Apolipoprotein A-1 precursor poly-
peptide,  and  the  mitochondrial  ZnCu-Superoxide 
dismutase were also expressed by tumor and normal 
cells (data not shown).  Journal of Cancer 2010, 1 
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Table 2. Proteins identified by MALDI-TOF that showed significant (p<0.05) upregulation between RCC and the cor-
responding normal kidney tissue 
Spot ID  Histology  Protein name  Swiss-Prot Ac-
cession number 
Fold-change  MW/pI (experi-
mental) 
MOWSE 
score 
Number of 
peptides 
matched (To-
tal no. of 
peptides) 
Sequence 
coverage 
CC1  Clear Cell 
RCC 
Heat shock protein 27 
(Hsp27) 
P04792  11.1  22,327 / 7.8  6.666e+04  11 (22)  42% 
CC2  Clear Cell 
RCC 
Triosephosphate isome-
rase 1 (TPI-1) 
P60174  7.1  22,327 / 6.4  1.340e+04  8 (16)  37% 
CC3  Clear Cell 
RCC 
Beta globin (HBB)  P68873  10.9  15,999 / 6.7  4.982e+06  10 (20)  76% 
CC4  Clear Cell 
RCC 
Peroxiredoxin 2 (PRX-2)  P32119  2.1  21,892 / 5.6  3.237e+04  9 (18)  36% 
CC5  Clear Cell 
RCC 
Apolipoprotein A1 pre-
cursor (Apo-A1) 
P02647  3.0  28,962 / 5.3  5.710e+07  17 (44)  57% 
CC6  Clear Cell 
RCC 
Ferritin Light polypeptide  Q6DMM8  8.9  20,020 / 5.5  4.726e+04  9 (19)  42% 
CC7  Clear Cell 
RCC 
Haptoglobin  P00738  8.0  38,234 / 6.1  200  5 (17)  9% 
CHR1  Chromophobe 
RCC 
ZnCu-Superoxide dis-
mutase (SOD2) 
Q7Z7M6  5.5  18,838 / 5.6  1134  5 (12)  43% 
CHR2  Chromophobe 
RCC 
UV excision repair protein 
RAD23B 
P54727  11.8  43,172 / 4.9  1.053e+05  11(31)  27% 
CHR3  Chromophobe 
RCC 
Alpha-1 anti-trypsin 
(SERPINA1) 
P01009  13.5  44,251 / 5.5  4.065e+04  8(22)  23% 
ONCO1  Oncocytoma  Alpha-Enolase (ENOA)  P06733  10.4  49,703 / 7.1  9.403e+05  12(34)  35% 
 
Table 3. Correlation of Hsp27 expression with some clinicopathological variables. 
Variable  Hsp27 IHC  p Value 
0 - 1+  2+ - 3+ 
N  %  N  % 
Age (yrs)           
≤50  4  16.0  11  44.0  0.614 
>50  1  4.0  9  36.0   
Sex           
Male  4  16.0  10  40.0  0.240 
Female  6  24.0  5  20.0   
Tumor size (cm)           
≤4  2  8.0  2  8.0  0.019 
4-7  0  0.0  14  56.0   
>7  0  0.0  7  28.0   
Histology           
Clear Cell  3  12.0  16  64.0  0.005 
Papillary  2  8.0  0  0.0   
Chromophobe  2  8.0  1  4.0   
Oncocytoma  1  4.0  0  0.0   
Fuhrman grade           
1-2  2  8.3  6  25.0  0.999 
3-4  4  16.7  12  50.0   
T category           
T1-T2  6  25.0  12  50.0  0.628 
T3-T4  1  4.0  5  21.0   
N category           
N0  6  24.0  15  60.0  0.569 
N1  2  8.0  2  8.0   
M category           
M0  3  12.0  9  36.0  0.410 
M1  6  24.0  7  28.0   
TNM stage           
I-II  4  17.0  7  29.0  0.142 
III-IV  1  4.0  12  50.0    Journal of Cancer 2010, 1 
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Figure 2. Immunohistochemical detection of Hsp27 in renal cell carcinomas. (A) Clear cell carcinoma showing strong 
cytoplasmic expression of Hsp27. B. A higher magnification to show the intense cytoplasmic and membrane staining. (C-D) 
A poorly differentiated clear cell carcinoma with sarcomatoid features also strongly expressing Hsp27. Expression in normal 
kidney was heterogeneous and restricted to some tubules (E). Glomeruli were consistently negative (F). A positive control 
RCC cell line pellet (786.O) formalin fixed and paraffin embedded demonstrating high Hsp27 expression (G). Iso-
type-matched negative control (H). Magnification: 5X for panels A and C; 16X for B, D, E-H. Journal of Cancer 2010, 1 
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Figure 3. Validation of TPI-1 expression in FFPE RCC tissues. TPI-1 positivity in clear cell carcinomas (A-D). The staining 
pattern is predominantly mixed cytoplasmic and nuclear (arrowheads). (E) Positve control (786.O cell line pellet) and 
isotype matched negative control (F). Magnification: 5X for A and C; 16X for B, D, E-F. 
 
 
Hsp27 and TPI-1 correlation with clinicopatho-
logical variables 
Immunohistochemical  analysis  showed  that  94 
p e r   c e n t   ( 1 6   o u t   o f   1 7 ) of Hsp27 positive cases were of 
clear  ce l l   t y p e   ( p=0.005).  Seventy-five  per  cent  of 
Fuhrman grade 3-4 cases were moderate or strongly 
positive for Hsp27. A l l   t u m o r s   > 4   c m   ( T 1 b ~ )   s h o w e d  
positivity  w h e n   c o m p a r e d   t o   s m a l l e r   t u m o r s  
(p=0.019).  Seventy-one  percent  of  strongly  positive 
cases f o r   H s p 2 7   w e r e   s t a g e   I I I   o r   IV. For Triosephos-
phate  isomerase 1,  87%  of  Fuhrman  3-4  cases  were 
strongly positive, with 94% (18 out of 19) of positive 
c a s e s   b e i n g   c l e a r   c ell  type  (p<0.001). There was an 
inverse correlation of TPI-1 immunostaining and dis-
ease progression: most of strongly positive cases were 
pT categories T1 or T2 (p=0.054) and 56% of strongly 
p o s i t i v e   c a s e s   w e r e   s t a g e   I   o r   I I . No significant corre-Journal of Cancer 2010, 1 
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l a t i o n   w a s   o b s e r v e d   b e t w e e n   H s p 2 7   o r   T P I -1 expres-
sion and lymph node metastasis, lymphatic invasion, 
or distant metastasis. S i g n i f i c a n t   c o r r e l a t i o n s   o f   H s p 2 7  
and TPI-1 with clinicopathologic factors are summa-
rized in Tables 3 and 4. No significant relationship for 
the  other  proteins  identified  (Apolipoprotein  A-1, 
Superoxide  dismutase,  Alpha-enolase  and  Peroxire-
doxin 2) was found. 
 
Table 4. Clinicopathologic correlation of TPI-1 expression in FFPE samples. 
Variable  TPI-1 IHC  p Value 
0-1  2-3 
N  %  N  % 
Age (yrs)           
≤50  2  8.0  13  52.0  0.450 
>50  0  0.0  10  40.0   
Sex           
Male  1  4.0  13  52.0  1.000 
Female  1  4.0  10  40.0   
Tumor size (cm)           
<4  0  0.0  4  16.0  1.000 
4-7  0  0.0  14  56.0   
>7  0  0.0  7  28.0   
Histology           
Clear Cell  1  4.0  18  72.0  <0.001 
Papillary  1  4.0  1  4.0   
Chromophobe  3  12.0  0  0.0   
Oncocytoma  1  4.0  0  0.0   
Furhman grade           
1-2  0  0.0  8  33.0  0.536 
3-4  2  8.0  14  58.0   
T category           
T1-T2  0  0.0  18  75.0  0.054 
T3-T4  2  8.0  4  17.0   
N category           
N0  3  12.0  18  72.0  0.166 
N1  2  8.0  2  8.0   
M category           
M0  5  20.0  7  28.0  0.695 
M1  7  28.0  6  24.0   
TNM stage           
I-II  2  8.0  9   38.0  0.210 
III-IV  6  25.0  7  29.0   
 
 
Discussion 
While a relatively infrequent malignancy, kidney 
cancer is distinguished by its complexity and its not-
ably unsatisfactory treatment options. During the last 
t w o   d e c a d e s ,   o u r   u n d e r s t a n d i n g   o f   t h e   d i s e a s e   h a s  
advanced due to the recognition of chromosomal and 
genetic aberrations in RCCs associated with histologic 
subtypes. Within this context, the search for markers 
t o   i m p r o v e   d i s e a s e   c l a s s i f i c a t i o n ,   a s   w e l l   a s   n e w   t h e-
rapeutic targets, is imperative. 
Proteomic profiling is now been widely accepted 
a s   a   t o o l   f o r   g a i n i n g   i n s i g h t   i n t o   t h e   d y n a m i c s   o f   p r o-
tein pattern changes reflecting complex cellular states, 
s u c h   a s   t u m o r   v e r s u s   n o r m a l   t i s s u e .   T h i s   t e c h n o l o g y  
has been implemented for profiling tumors of differ-
ent histology in order to define biomarkers which are 
particularly  important  for  the  development  of  early 
detection, diagnosis, and prognosis of tumors, and to 
define  therapeutic  cancer  treatment  modalities.  The 
characterization of new RCC-specific markers might 
a l l o w   f o r   a   b e t t e r   s u b c l a s s i f i c a t i o n   o f   t h e   d i s e a s e ,   f o r  
the  design  of  new  molecular  targeted  therapeutics, 
and for defining histologic and molecular correlates 
for patient selection in clinical trials for RCC. 
In this study we identified the expression pattern 
of metabolic enzymes and stress response proteins in 
samples from human RCC lesions of distinct subtypes 
using 2D-gel-based classical proteome analysis. Some 
o f   t h e s e   p r o t e i n s   h a v e   p r e v i o u s l y   b e e n   s h o w n   t o   h a v e  
an altered expression in smaller subs e t s   o f   c l e a r   c e l l  
RCC using whole tissue samples (13, 14). The earliest 
r e p o r t s   o n   t h e   a n a l y s i s   o f   p r o t e i n   e x p r e s s i o n   p a t t e r n s  Journal of Cancer 2010, 1 
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in RCC by 2D gel-based proteomics appeared in the 
late 1990’s (15), with ongoing reports on the subject 
throughout  the  first  half  of  this  decade  (14,  16-18). 
These have largely focused on the clear cell type of 
t u m o r s   w i t h   s a m p l e   s i z e s   v a r y i n g   f r o m   1   t o   2 8   ( m e-
d i a n = 8 )   s p e c i m e n s   p e r   s t u d y   (19),   a n d   o n l y   a   f e w   h a v e  
attempted to validate in independent samples some of 
the differentially expressed proteins found in the 2D 
gels. As mentioned earlier, significant changes have 
occurred in the past few years in the classification and 
u n d e r s t a n d i n g   o f   t h e   g e n e t i c   c h a n g e s   o c c u r r i n g   i n  
other  subtypes  of kidney tumors,  but  the  proteomic 
a p p r o a c h   h a s   n o t   b e e n   u s e d   c o n s i s t e n t l y   w i t h   t h e s e  
changes.  
T o   t h e   b e s t   o f   o u r   k n o w l e d g e ,   o n l y  two studies 
have examined the proteome of the various types of 
r e n a l   c e l l   c a r c i n o m a   b a s e d   o n   2 D -PAGE analysis of 
material from tissue samples. Seliger et al. (20) eva-
luated  25  renal  cell  carcinomas,  which  included  20 
clear cell, 1 chromophobe and 2 renal oncocytomas. 
Among  the  more  than  400  differentially  expressed 
proteins, a variable expression pattern of individual 
fatty  acid  binding  proteins  (FABPs)  was  detected. 
Three  patterns  of  change were detected: changes in 
o n e   t u m o r   t y p e   b u t   n o t   i n   t h e   o t h e r ,   w h i c h   o c c u r r e d  
f o r   t h e   H -s u b t y p e   o f   F A B P   ( H -FABP) in clear cell and 
oncocytomas;  downregulation  in  all  tumors  for 
L-FABP; and upregulation in all samples for B-FABP. 
They  noted  that  no  confident  matching  of  spots  for 
B-FABP was achieved in any of the samples analyzed, 
and the expression of only one of the three proteins 
could be validated in biopsy samples. However, in a 
RT-P C R   v a l i d a t i o n   s e t   o f   3 0   c a s e s ,   t h e r e   w a s   p o s i t i v e  
confirmation of the transcripts in 18 (60%), and strong 
amplicon bands were observed in only 10 (33%).  
Zhuang e t   a l . (21) suggested individual proteome 
profiles for the different RCC subtypes, which were 
defined by the presence, absence, up- or downregula-
t i o n   o f   i n d i v i d u a l   p r o t e i n s   i n   o n e   t u m o r   s u b s e t   b u t  
n o t   i n   o t h e r   s u b t y p e s   o r   i n   n o r m a l   k i d n e y   e p i t h e l i u m .  
H o w e v e r ,   t h e i r   c o n c l u s i o n   w a s   b a s e d   o n   t h e   a n a l y s i s  
of a limited number of samples for each histological 
subtype (n=3), and no validation of the differentially 
expressed proteins was achieved.  
We  have  used  rather  stringent  criteria  for  de-
tecting differentially expressed proteins for intra-class 
and  inter-class  comparison,  which  may  explain  the 
reduced number of protein identifications compared 
t o   p r e v i o u s   s t u d i e s .   I n   t h e   w o r k   o f   U n w i n   et al. (22), 
only 18 proteins were identified initially as differen-
tially upregulated in all of the samples used, but the 
n u m b e r   o f   p r o t e i n s   i n c r e a s e d   t o   3 2   a f t e r   r e l a x i n g   c r i-
t e r i a   o f   d i f f e r e n t i a l   e x p r e s s i o n .   I n   a   l a t e r   r e p o r t   f r o m  
t h e   s a m e   g r o u p   (20), the identified proteins were sig-
nificantly  either  up  or  downregulated  more  that 
2-fold  (a  widely  accepted  threshold  for  significant 
change) in only three to five of the 25 tumor-normal 
pairs.  
M a n y   o f   t h e   i d e n t i f i e d   p r o t e i n   c h a n g e s   i n   o u r  
samples were seen in metabolic enzymes involving 
glycolysis  and  oxidative  phosphorylation.  Some  of 
these changes have been previously reported in RCC 
based on enzyme activity analysis (22), but the protein 
e x p r e s s i o n   d a t a   i n   t h i s   s t u d y   n o t   o n l y   c o n f i r m s   t h e s e  
reports, but also provides more comprehensive evi-
dence  of  impaired  mitochondrial  function  and  in-
creased  dependence  on  glycolysis  as  a  source  of 
energy in RCC cancer cells. In addition to supporting 
a   d i s r e g u l a t i o n   o f   m i t o c h o n d r i a l   e n z y m e s   i n v o l v e d   i n  
oxidative phosphorylation, enzymes involved in oth-
e r   c e l l   e n e r g y   c y c l e s   ( i n c l u d i n g   f a t t y   a c i d   a n d   a m i n o  
a c i d   m e t a b o l i s m )   w e r e   a l s o   f o u n d   t o   b e altered. Such 
metabolic  alterations  may  underlie  the  cytoplasmic 
accumulation  of  lipids,  glycogen,  and  mitochondria 
characteristic of various RCCs.  
I n   o r d e r   t o   c o n f i r m   o u r   p r o t e o m i c   a n a l y s i s   r e-
sults,  we  examined  by  immunohistochemistry  two 
separate prote i n s   w h i c h   w e r e   f o u n d   t o   b e   s i g n i f i c a n t l y  
altered by 2D gel electrophoresis and MS identifica-
tion. These two proteins, Hsp27 and TPI-1 were se-
lected because they represented the family class or the 
functional annotation class. Our results highlight an 
Hsp27   o v e r e x p r e s s i o n   i n   R C C   c o m p a r e d   t o   t h e   h o-
mologous normal tissue. Khan e t   a l . (23) detected high 
levels of Hsp27 in the proximal tubular epithelium, 
podocytes, endothelial cells of vessels, and glomeruli 
(podocytes,  endothelial and  mesangial cells)  of  nor-
mal  kidney.  By  contrast,  in  our  samples  glomeruli 
were consistently negative for Hsp27 immunoreactiv-
i t y .   I n   o t h e r   s t u d y ,   E r k i z a n   e t   a l . (24) evaluated 7 6   R C C  
tissue  specimens,  and  the  presence  of  Hsp27  was 
d e m o n s t r a t e d   i n   7 3   ( 9 6 % )   o f   t h e m .   T h e   e x p r e s s i o n  
w a s   e i t h e r   i n t e r m e d i a t e   o r   h i g h   ( i . e   > 5 0 %   o f   t u m o r  
c e l l s )   i n   8 8 %   o f   t h e   c a s e s   a n d   w a s   g r e a t e r   i n   R C C   t i s-
sue compared with adjacent noncancerous renal tis-
sue. An inverse relationship was found between tu-
mor stage and Hsp27 expression, but no statistically 
significant  difference  was  observed  in  progres-
sion-free survival. I t   i s   n oteworthy that even though 
t h e   a u t h o r s   a n a l y z e d   5 0   c l e a r   c e l l   R C C ,   9   p a p i l l a r y , 
and  11  chromophobe  tumors,  their  results  were 
pooled rather than analyz e d   b y   h i s t o l o g i c   s u b t y p e .  In 
our study,   n o   r e l a t i o n s h i p   w a s   f o u n d   b e t w e e n   H s p 2 7  
expression and tumor grade, lymph node metastasis, 
distant metastasis, or cause-specific survival.  
Our  results  are  in  agreement  with  those  pub-
lished b y   S a r t o   e t   a l . (14),   i n   t h a t  Hsp27, evaluated in 15 
clear cell RCC samples, was widely expressed in the Journal of Cancer 2010, 1 
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tubular structures, cytoplasm, cell membrane and the 
endothelium  of  the  vessels,  but  was  systematically 
non-reactive in g l o m e r u l i .   T h e   m a j o r i t y   o f   t h e   r e n a l  
c e l l   c a r c i n o m a s   i n   t h e i r   c o h o r t   s h o w e d   d i f f u s e   b u t  
strong Hsp2 7   i m m u n o r e a c t i v i t y   i n   m o r e   t h a n   5 0 %   o f  
neoplastic cells.  
Levels of Hsp27 have also been reported to be 
elevated not only in kidney cancer (14, 25) but also in 
other  solid  tumors,  including  breast  (26), liver (27), 
ovary  (28)  prostate  (29)  and  bladder  (30),  amongst 
others.  
Heat shock proteins (HSP), also termed molecu-
lar  chaperones,  are  a  group  of  several  ubiquitous 
proteins originally correlated to increased resistance 
t o   t h e r m a l   s h o c k   i n   d a m a g e d   c e l l s .   H S P s   c a n   b e   i n-
duced by different cellular insults including increased 
temperature, oxidative stress, or pathological condi-
tions, such as ischemia, inflammation, tissue damage, 
infection  and  neoplastic  transformation  (31).  Fur-
thermore, HSPs are involved in several cellular func-
tions, including the regulation of cellular homeostasis 
a n d   a p o p t o s i s ,   a n d   p l a y   a n   i m p o r t a n t   r o l e   i n   t u m o r  
antigenicity  (32).  Specifically,  Hsp27  is  involved  in 
A c t i n   o r g a n i z a t i o n ,   w h i c h   a p p e a r s   t o   b e   i t s   m a i n  
physiological function (33), and is phosphorylated in 
r e s p o n s e   t o   h e a t   s h o c k   a n d   e x p o s u r e   t o   o t h e r   s t i m u l i  
such as cytokines, growth factors, angiogenesis inhi-
bitors and peptide hormones (34, 35).  
Triosephosphate  Isomerase 1 (TPI-1 )   i s   t h e   e n-
zyme  that  catalyzes  the  reversible  transformation  of 
D-3-glyceraldehyde phosphate into dihydroxyacetone 
phosphate.  Dihydroxyacetone  phosphate  is  then 
transformed  into  D-3-glyceraldehyde  phosphate  to 
continue the glycolytic pathway, which  explains  the 
i m p o r t a n c e   o f   T P I -1   i n   t h e   p r o c e s s   o f   g l y c o l y s i s   (36). 
Changes in enzyme activity have been reported in a 
series  of  normal  and  pathological  conditions,  and 
overexpression of TPI-1 may well relate to increased 
requirements  of  b o t h   e n e r g y   a n d   p r o t e i n   s y n t h e-
sis/degradation pathways in rapidly growing tumors 
(37).  However,  the  exact  mechanism(s)  that  regu-
l a t e ( s )   e x p r e s s i o n   o f   t h i s   e n z y m e   i n   R C C s   i s   y e t   u n-
clear.  
F i n a l l y ,   w e   g e n e r a t e d   a   V e n n   d i a g r a m   t o   i d e n t i f y  
commonly expressed proteins in RCC from the results 
published in the literature. Intersection of curated lists 
demonstrating upregulated proteins is shown in Fig. 
4.  Fo u r   p r o t e i n s   ( H s p 2 7 ,   T P I -1,  Alpha-Enolase  and 
SOD),  including  two  which  were  validated  in  the 
present study, w e r e   f o u n d   a s  common denominators 
in  these  lists,  and  taken  together,  these  results  add 
c o n f i d e n c e   f o r   t h e   r o l e   o f   H s p 2 7   a n d   T P I -1 expression 
in clear cell renal cell carcinomas.  
 
Figure 4. Venn diagram to intersect the lists of upregulated 
proteins generated in the present study and two others 
from published proteomic articles on RCC. Four proteins: 
Hsp27, TPI-1, Alpha-E n o l a s e   a n d   S O D ,   t w o   o f   t h e m   v a l i-
dated in the present study, were common to these three 
datasets. 
 
A l t h o u g h   o u r   r e s u l t s   c o n f i r m   a n d   e x p a n d   p r e-
vious findings, the main contribution of the present 
work  is  the  inclusion  in  the  proteomic  analysis  of 
R C C s   w i t h   d i s t i n c t   h i s t o l o g y .   C o m p a r e d   t o   t h e   s t u-
d i e s   p u b l i s h e d   t o   d a t e ,   o u r   p r o t e o m i c   a n a l y s i s   h a s  
included an adequate sample size for generating put-
a t i v e   b i o m a r k e r s   f o r   e a c h   R C C   h i s t o l o g i c   s u b t y p e ,  
which have been validated in an independent cohort 
of kidney tumors. In both groups, statistical power for 
detecting  differences  amongst  groups  of  samples 
support the assumption that these markers are indeed 
differentially expressed.  
There are limitations on the generalized use of 
the  surrogate markers identified in this study. First, 
the number of tumor lesions analyzed in the present 
w o r k   a n d   i n   t h e   l i t e r a t u r e   s o   f a r   i s   t o o   s m a l l   t o   e s t a b-
lish valuable associations between clinicopathological 
parameters and a given protein profile. Second,  we 
r e c o g n i z e   t h a t   o u r   p r o t e o m i c   a n a l y s i s   i s   n o t   e x h a u s-
tive, and is biased toward identification of high ab-
undance soluble proteins. However, high-abundance 
p r o t e i n s ,   w h i c h   a r e   a l t e r e d   i n   R C C   a r e   t h o s e   w h i c h   a r e  
m o s t   l i k e l y   t o   h a v e   a n   i m p a c t   o n   R C C -specific altera-
t i o n   o f   c e l l u l a r   p h e n o t y p e .   F u t u r e   w o r k   n e e d s   t o   a d-
dress the issues of examining underrepresented pro-
t e i n s ,   o r   t h e   i s s u e   o f   d i f f e r e n t i a l   p o s t -translational Journal of Cancer 2010, 1 
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modifications for a better understanding of their role 
in RCCs. 
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